Real-World Effectiveness of Gliclazide MR vs. Sitagliptin as Second-Line Therapy in People with Type 2 Diabetes Uncontrolled on Metformin

被引：0
|
作者：
Zaccardi, Francesco
Cortese, Viviana
Jacquot, Emmanuelle
Tyrer, Freya
Seidu, Samuel
Davies, Melanie J.
Khunti, Kamlesh
机构：
来源：
DIABETES | 2020年 / 69卷
关键词：
D O I：
10.2337/db20-1062-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1062-P
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Durable antidiabetic effect of Glyburide/Metformin tablets as second-line therapy for type 2 diabetes
    Blonde, L
    Rosenstock, J
    Piper, BA
    Henry, D
    DIABETES, 2001, 50 : A106 - A106
  • [22] Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea
    Khaloo, P.
    Komeleh, S. Asadi
    Alemi, H.
    Mansournia, M. A.
    Mohammadi, A.
    Yadegar, A.
    Afarideh, M.
    Esteghamati, S.
    Nakhjavani, M.
    Esteghamati, A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2019, 42 (07) : 851 - 857
  • [23] Real-world Positioning and Effectiveness of First- and Second-Line Biological Therapy in Inflammatory Bowel Diseases
    Reves, Joana
    Torres, Joana
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (06): : 787 - 789
  • [24] Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States
    Reifsnider, Odette
    Kansal, Anuraag
    Pimple, Pratik
    Aponte-Ribero, Valerie
    Brand, Sarah
    Shetty, Sharash
    DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 791 - 799
  • [25] ERLOTINIB VS DOCETAXEL AS SECOND-LINE TREATMENT OF ADVANCED NSCLC: A REAL-WORLD COST-EFFECTIVENESS STUDY
    Cromwell, Ian
    Van der Hoek, Kimberly
    Melosky, Barbara
    Peacock, Stuart
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1181 - S1182
  • [26] Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study
    El Ebrashy, Ibrahim
    El Kafrawy, Nabil
    Raouf, Rana
    Yousry, Diana
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 162
  • [27] UPTAKE OF NEWER SECOND-LINE DIABETES MEDICATIONS IN REAL-WORLD VULNERABLE POPULATIONS
    Ogunsanmi, D.
    Harrison, A. T.
    Kovesdy, C. P.
    Surbhi, S.
    VALUE IN HEALTH, 2022, 25 (07) : S499 - S499
  • [28] Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia
    Bekele, Mengistu
    Norheim, Ole Frithjof
    Hailu, Alemayehu
    MDM POLICY & PRACTICE, 2021, 6 (01)
  • [29] Dapagliflozin plus saxagliptin plus metformin triple therapy vs sitagliptin add-on to metformin dual therapy in subgroups of patients with uncontrolled type 2 diabetes
    Del Prato, S.
    Handelsman, Y.
    Mathieu, C.
    Johnsson, E.
    Kurlyandskaya, R.
    Iqbal, N.
    Garcia-Sanchez, R.
    Rosenstock, J.
    DIABETOLOGIA, 2017, 60 : S20 - S21
  • [30] Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives
    Khunti, Kamlesh
    Hassanein, Mohamed
    Lee, Moon-Kyu
    Mohan, Viswanathan
    Amod, Aslam
    DIABETES THERAPY, 2020, 11 (SUPPL 2) : S33 - S48
12345